Výsledky vyhľadávania - "Proteasome Inhibitors adverse effects"

Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis

Autori: Wickel, Jonathan Chung, Ha-Yeun Platzer, Stephanie a ďalší

Zdroj: Trials 21(1), 625 (2020). doi:10.1186/s13063-020-04516-7

Predmety: info:eu-repo/classification/ddc/610, Acyclovir, Adult, Autoantibodies: blood, Bortezomib: adverse effects, Bortezomib: therapeutic use, Clinical Trials, Phase II as Topic, Dexamethasone, Double-Blind Method, Drug Therapy, Combination, Encephalitis: drug therapy, Encephalitis: immunology, Germany, Glasgow Coma Scale, Hashimoto Disease: drug therapy, Hashimoto Disease: immunology, Humans, Immunotherapy, Multicenter Studies as Topic, Prospective Studies, Proteasome Inhibitors: adverse effects, Proteasome Inhibitors: therapeutic use, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Trimethoprim, Sulfamethoxazole Drug Combination

Geografické téma: DE

Relation: info:eu-repo/semantics/altIdentifier/issn/1745-6215; info:eu-repo/semantics/altIdentifier/issn/1468-6708; info:eu-repo/semantics/altIdentifier/pmid/pmid:32641101; info:eu-repo/semantics/altIdentifier/issn/1468-6694; https://pub.dzne.de/record/153279

Dostupnosť: https://pub.dzne.de/record/153279
https://pub.dzne.de/search?p=id:%22DZNE-2020-01276%22

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Autori: Redelman-Sidi, G. Michielin, O. Cervera, C. a ďalší

Predmety: Antibodies, Monoclonal/adverse effects, Monoclonal/therapeutic use, Monoclonal, Humanized/adverse effects, Humanized/therapeutic use, Biological Therapy/adverse effects, Biological Therapy/methods, CTLA-4 Antigen/antagonists & inhibitors, Cell Adhesion/drug effects, Clinical Trials as Topic, Communicable Diseases/therapy, Consensus, Genes, cdc/drug effects, Humans, Immunocompromised Host, Leukoencephalopathy, Progressive Multifocal/therapy, Molecular Targeted Therapy/adverse effects, Molecular Targeted Therapy/methods, Natalizumab/adverse effects, Natalizumab/therapeutic use, Proteasome Inhibitors/adverse effects, Proteasome Inhibitors/therapeutic use, Receptors, Lysosphingolipid/drug effects, Alefacept, Fingolimod, Infection

Relation: Clinical Microbiology and Infection; https://iris.unil.ch/handle/iris/162531; serval:BIB_679ECFFACD23; 000454246100009

Dostupnosť: https://iris.unil.ch/handle/iris/162531
https://doi.org/10.1016/j.cmi.2018.01.030

Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.

Autori: Burkhart T Keith MCL Lenneman CAG a ďalší

Zdroj: Texas Heart Institute journal [Tex Heart Inst J] 2018 Aug 01; Vol. 45 (4), pp. 260-263. Date of Electronic Publication: 2018 Aug 01 (Print Publication: 2018).

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: eCollection Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE

Výrazy zo slovníka MeSH: Bortezomib/*adverse effects , Cardiac Tamponade/*chemically induced , Graft vs Host Disease/*drug therapy , Pericardiocentesis/*methods , Surgery, Computer-Assisted/*methods, Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Bortezomib/therapeutic use ; Cardiac Tamponade/diagnosis ; Cardiac Tamponade/surgery ; Echocardiography, Doppler ; Fluoroscopy ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy ; Male ; Middle Aged